Claya Review
Best for: Patients seeking a compounded GLP-1 platform with named clinician leadership and named pharmacy partners who want both injectable and oral-tablet form factors, and who are comfortable with the standard 503A-compounded supply chain.
Claya (claya.com) is a direct-to-consumer GLP-1 telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms. Compounded semaglutide injectable starts at $179/month (first month), oral tablets at $279/month; compounded tirzepatide injectable at $279/month, oral tablets at $379/month. Refills lock at $299/month. Pricing is bundled with provider consultation and 'free, expedited delivery' per the homepage. Named medical leadership: Jennifer Habashy NMD MS and Dr. Michael Barber MD PhD — unusual transparency for a compounded-GLP-1 marketplace. Pharmacy partners disclosed by name: RedRock Pharmacy (1240 E 100 S #220, St. George, UT 84790) and Healthware House (7107 Industrial Rd., Florence, KY 41042). Corporate address: 317 6th Ave Ste 400, Des Moines, IA 50309 (with alternate partner-operations address at 2345 Via Inspirada, Unit 130, Henderson, NV 89044). LLC/Inc/PC designation is NOT explicitly disclosed on the site. Tagline: 'Fat loss made easy with personalized care' with a 'Weight Loss Money Back Guarantee.' Brand-name Wegovy/Ozempic/Mounjaro/Zepbound are referenced as comparator products but Claya sells the compounded versions. Live-verified 2026-05-19.
Medium confidence · Last verified 2026-05-19 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Claya is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Claya prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| First month introductory | compounded | $179 |
| Refill (locked rate) | compounded | $299 |
| Oral tablet (first month) | compounded-oral | $279 |
| First month introductory | compounded | $279 |
| Refill (locked rate) | compounded | $299 |
| Oral tablet (first month) | compounded-oral | $379 |
✓ Pros
- •Two named licensed clinicians (Habashy NMD MS and Barber MD PhD) — rare transparency for a compounded-GLP-1 platform
- •Two named 503A-pattern pharmacy partners with full addresses (RedRock UT + Healthware KY)
- •Both injectable AND oral-tablet compounded formulations offered for both semaglutide and tirzepatide
- •Weight-loss money-back guarantee published on homepage
- •Free expedited shipping included in monthly price
✗ Cons
- •States-served list NOT disclosed on homepage or FAQ — buyers must check at checkout
- •LegitScript certification status NOT displayed on homepage
- •Corporate legal entity (LLC/Inc/PC) NOT disclosed on site or in privacy policy
- •Compounded oral tablets are an aggressive form factor — efficacy data vs injectable semaglutide is weaker (no STEP-equivalent oral compounded trials)
- •Tiered pricing structure (intro vs refill) creates first-month price advantage that disappears at refill
Ready to start with Claya?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our Claya review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Claya
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Claya?
Starting at $179/month. See current pricing and start your free consultation.